Skip to main content

Table 7 Multivariate Cox regression model of the main adverse events stratified by CMBs

From: The safety of antithrombotic therapy in patients with cerebral microbleeds and cardiogenic cerebral embolism due to nonvalvular atrial fibrillation

  All-cause death CH events
non- CMBs CMBs P value P interaction non- CMBs CMBs P value P interaction
Gender     0.718     0.447
 Male 1 1.099 (0.398–3.034) 0.885   1 2.228 (0.785–6.326) 0.132  
 Female 1 1.819 (0.603–5.931) 0.275   1 1.712 (0.575–5.096) 0.334  
Smoking     0.143     0.656
 Yes 1 0.679 (0.375–1.233) 0.300   1 1.219 (0.304–4.884) 0.780  
 No 1 1.940 (0.830–4.534) 0.126   1 2.075 (0.886–4.858) 0.894  
Hypertension history     0.054     0.034
 Yes 1 0.856 (0.748–4.605) 0.182   1 3.451 (1.947–6.119) 0.045  
 No 1 0.715 (0.236–2.165) 0.357   1 0.658 (0.135–3.210) 0.605  
Diabetes history     0.224     0.183
 Yes 1 2.004 (0.638–6.295) 0.234   1 2.388 (0.657–8.683) 0.186  
 No 1 0.563 (0.150–2.109) 0.394   1 1.437 (0.560–3.685) 0.274  
CI history     0.170     0.825
 Yes 1 1.471 (0.356–6.079) 0.594   1 2.208 (0.199–24.472) 0.519  
 No 1 1.309 (0.532–3.223) 0.558   1 1.602 (0.756–3.394) 0.219  
CH history     0.015     0.018
 Yes 1 2.773 (1.056–7.280) 0.019   1 2.443 (1.078–5.536) 0.006  
 No 1 1.258 (0.564–2.805) 0.575   1 1.565 (0.751–3.261) 0.232  
Anticoagulant therapy     0.415     0.147
 Yes 1 1.476 (0.394–5.526) 0.563   1 2.004 (0.814–4.936) 0.131  
 No 1 0.838 (0.329–2.134) 0.711   1 1.492 (0.443–5.024) 0.519  
NIHSS score     0.770     0.448
 ≤ 4 1 0.852 (0.229–3.178) 0.812   1 2.338 (0.604–9.047) 0.101  
 ≥ 5 1 2.505 (0.783–8.015) 0.122   1 3.077 (1.071–8.844) 0.037